Isotopia Molecular Imaging Limited (Isotopia) and Jubilant Radiopharma, a division of Jubilant Pharma Limited, have entered into a strategic commercial partnership to increase their portfolio of nuclear medicine products and expand their commercial footprint in North America. As Part of the agreement, Jubilant will have an exclusive license to market Isotopia's Theranostic products in the US.
"The capability of cold kit innovation and therapeutic isotopes in mass production will allow a strategic partnership between Jubilant Radiopharma and Isotopia as a significant milestone in our company's history," said Dr. Eli Shalom, Isotopia's chief executive officer and co-founder. "By partnering with a well-established industry leader such as Jubilant, Isotopia will be able to penetrate to the U.S. market and to deliver breakthrough compounds to the nuclear medicine community that will significantly benefit patients and their families."
"The combination of Isotopia's long history of innovation in theranostic products and Jubilant's strong commercial capabilities and resources, will enable the development of game changing radiotherapeutics that will advance the field of nuclear medicine" stated Sergio Calvo, president of Jubilant's Radiopharmaceuticals Division.Back To Top
Jubilant Radiopharma and Isotopia Molecular Join Forces to Expand North American Footprint. Appl Rad Oncol.